205 related articles for article (PubMed ID: 25837771)
21. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
[TBL] [Abstract][Full Text] [Related]
22. Surface plasmon resonance analysis of seven-transmembrane receptors.
Aristotelous T; Hopkins AL; Navratilova I
Methods Enzymol; 2015; 556():499-525. PubMed ID: 25857797
[TBL] [Abstract][Full Text] [Related]
23. SPR-based fragment screening: advantages and applications.
Neumann T; Junker HD; Schmidt K; Sekul R
Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
[TBL] [Abstract][Full Text] [Related]
24. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
25. Protein-Ligand Interactions Using SPR Systems.
Frostell A; Vinterbäck L; Sjöbom H
Methods Mol Biol; 2013; 1008():139-65. PubMed ID: 23729252
[TBL] [Abstract][Full Text] [Related]
26. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Kamada Y; Sakai N; Sogabe S; Ida K; Oki H; Sakamoto K; Lane W; Snell G; Iida M; Imaeda Y; Sakamoto J; Matsui J
J Med Chem; 2017 May; 60(10):4358-4368. PubMed ID: 28471657
[TBL] [Abstract][Full Text] [Related]
27. Fragment-based screening using surface plasmon resonance technology.
Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
[TBL] [Abstract][Full Text] [Related]
28. [Progress in the fragment-based drug discovery].
Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
30. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products.
Murray JB; Roughley SD; Matassova N; Brough PA
J Med Chem; 2014 Apr; 57(7):2845-50. PubMed ID: 24520903
[TBL] [Abstract][Full Text] [Related]
31. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
[TBL] [Abstract][Full Text] [Related]
32. Biophysical screening for the discovery of small-molecule ligands.
Ciulli A
Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
[TBL] [Abstract][Full Text] [Related]
33. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
34. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
36. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
[TBL] [Abstract][Full Text] [Related]
37. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
38. Rapid identification of ligand-binding sites by using an assignment-free NMR approach.
Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H
J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460
[TBL] [Abstract][Full Text] [Related]
39. Affinity classification of kinase inhibitors by mass spectrometric methods and validation using standard IC(50) measurements.
Jecklin MC; Touboul D; Jain R; Toole EN; Tallarico J; Drueckes P; Ramage P; Zenobi R
Anal Chem; 2009 Jan; 81(1):408-19. PubMed ID: 19067573
[TBL] [Abstract][Full Text] [Related]
40. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
